Investor Ideas #Potcasts 599, #Cannabis News and #Stocks on the Move; (NASDAQ: $HUGE) (CSE: $HUGE.C), (TSX: $FAF.TO) (TSXV: $BEER.V) (TSX: $TGOD.TO) (OTC: $TGODF)
Delta, Kelowna, BC, August 26, 2021 (Investorideas.com Newswire) www.Investoride, as.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/082621-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/08261HUGE-FAF-BEER-TGOD.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF), a leading producer of premium certified organically grown cannabis, announced that it completed its first international commercial shipment consisting of cannabis flower and other extracts destined for the highly anticipated South African medical cannabis market.
TGOD's cannabis flower will be the first to be distributed legally in the country at a commercial scale. Its products received the approval of the South African Health Products Regulatory Authority (SAHPRA). This illustrates the value of TGOD's organic portfolio and bolsters its position in securing international market access. TGOD continues to see demand and opportunities for superior quality, high potency, and consistent products, which the CleanCraft™ processes enable TGOD to deliver.
"This is an important milestone in our strategy to export our certified organically grown medical cannabis products to international markets. We are confident that our in-country partner will continue to develop this nascent market and that TGOD's portfolio of products will be well received by patients that have previously lacked access to legal, high-quality medical cannabis " commented Sean Bovingdon, TGOD's CEO and Interim CFO. "We are pleased to be able to complete our first shipment mid-Q3 2021, in line with our corporate objectives. This is setting the base for our large-scale commercialisation into the international market in 2022," added Bovingdon.
Hill Street Beverage Company Inc. (TSXV: BEER) announced that its California licensee - Trinidad Consulting LLC, has started production in preparation to launch a new THC infused line of its top-selling Cannadips products. Powered by DehydraTECH™ fast-acting technology through a licensing agreement with Hill Avenue Cannabis, this latest innovation follows the extremely successful use of DehydraTECH™ technology in their national CBD product lineup.
Based in Humboldt County, California, Cannadips is the leading brand of smokeless nicotine and tobacco free dips in the United States. The company currently manufactures and distributes their popular CBD brand through exclusive licensee, Boldt Runners Corporation, in over 5,500 stores across the US. The modern oral pouch category is growing exponentially in the US, representing a $7 billion market category comprised of 6.5 million smokeless tobacco users. With the launch of the new THC line, Cannadips continues to lead innovation in the category, further pioneering the modern dip alternative.
"We're delighted that this latest Cannadips innovation is powered by DehydraTECH™," said Craig Binkley, Co-CEO of Hill Street. "Our mission is to partner with brands that are driven to deliver premium quality and category leading performance. Cannadips aligns perfectly with these values as they constantly pursue the highest craft quality combined with the most advanced technology to ensure that consumers enjoy a superior experience. Cannadips has already proven that DehydraTECH™ technology is superior through their highly successful CBD product lineup."
Patented DehydraTECH™ technology improves the way active pharmaceutical ingredients (APIs) enter the bloodstream, delivering advantages such as faster onset and more predictable cannabis experiences for consumers.
"Delivering best in category value propositions is of utmost importance to us," said Case Mandel, co-founder of Cannadips. "In our quest to create the ultimate smokeless, oral cannabinoid experience for our customers, we found that DehydraTECH™ is the perfect technology for our products and is hands-down the highest performing technology we have tried. It preserves the valuable terpenes found in our cannabis extracts and increases cannabinoid bioavailability, allowing for quick absorption directly in the mouth."
The moment is right for launching Cannadips THC, as the Cannadips brand has strong awareness with CBD/hemp consumers which will provide a halo effect when it arrives in California dispensaries statewide. Cannadips has developed strong partnerships that will allow both speed to market and best in class sales and distribution. Their manufacturing partner ArcataX Inc provides best in class manufacturing and an exclusive distribution deal with Herbl, the largest cannabis supply chain company in California, will be key drivers of success at retail.
"At Hill Street we have a strong conviction to work with brands that matter. We believe in the power of cannabis and best in class science to create product alternatives that are both better and better for you", said Lori Senecal, Co-CEO of Hill Street. "The Cannadips products are a shining example of this commitment. They offer adult consumers a high quality product and a better alternative to tobacco and nicotine with CBD and now THC infused options. We're delighted that, with this launch, California becomes the next state where DehydraTECH™ THC will be active in the market."
The Cannadips THC line will initially be available in two strengths. The mega-dose cans will have 500mg of THC resulting in 25mg per pouch and the daily dose offering will contain 150mg of THC per can, or 10mg per pouch. The new line-up is anticipated to make its debut at the Hall of Flowers in late September and become available for pre-order before rolling out statewide in California in October 2021.
Fire & Flower Holdings Corp. (TSX: FAF) (OTCQX: FFLWF) and its wholly-owned subsidiary Hifyre™ Inc., today announced the proposed acquisition of all issued and outstanding shares of PGED Corp., ("PotGuide"), one of the world's largest cannabis websites and content platforms.
PotGuide is one of the most visited cannabis websites in North America, as reported by industry-standard online traffic tools. Along with the proposed acquisition of certain assets of Wikileaf Technologies Inc. announced earlier this month, the Hifyre digital network will become one of the world's most visited networks of cannabis websites and content platforms.
Upon closing, the Acquisition is expected to be immediately accretive to the Company's revenue and profitability and will provide Hifyre with a U.S. base for technology and operations.
Following closing of the Acquisition, Hifyre intends to leverage this significant user traffic and its proprietary white-label dispensary e-commerce software to convert traffic into cannabis and accessory purchases. The purchases will be fulfilled by the Fire & Flower retail network across Canada and in California through its agreement with Fire & Flower U.S. Holdings Inc. Hifyre anticipates creating additional agreements with dispensary networks across Canada and the U.S. to fulfill cannabis purchases in as many geographic locations as possible.
PotGuide and Wikileaf bring an existing subscriber base of approximately 225,000 cannabis consumers into the Spark Perks™ ecosystem. Subscribers will be invited to enroll in the Company's Spark Perks™ member program, which already boasts over 300,000 subscribers. The program allows members to unlock unique benefits and helps Hifyre build a greater understanding of cannabis consumer preferences across North America as part of the Hifyre IQ data program.
"As Fire & Flower has grown over the past few years, we have successfully proven the value of our Hifyre data analytics retail platform and it is a great accomplishment to see the rapid success of our expanding digital strategy with the acquisition of PotGuide," shared Trevor Fencott, Chief Executive Officer of Fire & Flower. "Now that we are strategically acquiring two of the most visited cannabis online websites, PotGuide and Wikileaf, we have established Fire & Flower and Hifyre as leading global players in digital cannabis traffic and believe we can offer even greater value to these high-demand properties."
"PotGuide is excited to join the Fire & Flower and Hifyre network of properties and we look forward to continuing to build one of the leading North American cannabis technology companies," shared Jeremy Bamford, Chief Executive Officer of PGED Corp. "The ability to leverage the significant web traffic of PotGuide.com with Hifyre's cannabis e-commerce technology will enable us to offer an increased value proposition to our users and enhance the growth strategy of our business."
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announced that it has entered a definitive agreement to acquire 100% of the issued and outstanding shares Lucid Psycheceuticals Inc., a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for approximately US$9 million (CAD$11.3 million) in FSD Pharma stock (the "Transaction"), as further described below.
"The acquisition of a distinctive company like Lucid illustrates FSD Pharma’s vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative diseases in a new way," said Anthony Durkacz, Interim CEO of FSD Pharma. "Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies. This is an exciting venture for FSD Pharma that we believe represents a paradigm shift in the development and outlook of our company."
Founded in 2020, Lucid is developing novel molecules and combinations with the goal of addressing Total Brain Health and targeting some of the most challenging neurodegenerative diseases, such as Multiple sclerosis, and other Brain conditions. Lucid has exclusive worldwide licensing rights from the University Health Network, North America’s largest health research organization, to a patent-protected family of new chemical entities (NCEs), on which Lucid’s development platform is based and from which its lead neurodegenerative disorders therapeutic candidate, Lucid-21-302, has been derived. In addition, Lucid’s pipeline includes Lucid-201, a psychedelic drug candidate targeting mental health disorders, and it is also investigating certain cannabinoids.
In addition, upon closing of the transaction Lucid’s co-founder and CEO, Dr. Lakshmi Kotra will be transitioning to the FSD Pharma team with Prof. Kotra taking on the role of leading the development of FSD Pharma’s drug development pipeline in Psychedelics and Medical Cannabis. Dr. Kotra is a Professor of Medicinal Chemistry at the University of Toronto, and senior scientist at Krembil Brain Institute at the University Health Network.
Prof. Lakshmi Kotra, co-founder and CEO of Lucid, commented, "We started with a vision to accelerate therapies for Total Brain Health. Since inception, we have made significant progress and built a strong scientific and execution team. We are excited to enter a new phase of growth with FSD Pharma. I am personally delighted with FSD Pharma leadership’s shared commitment to bring forward advanced therapeutics addressing challenging health issues. We believe our combined resources and experienced teams will position us to enter clinical development programs to deliver highly effective therapeutic products in neurodegenerative disorders and mental health areas."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
